Table 8.
Non-randomized studies with combinations of pegylated liposomal doxorubicin (PLD) and non-platinum agents
| Author | Drugs/dose | No. | RR (%) | PFS mts | % Grade 3/4 toxicity/patient |
|||
|---|---|---|---|---|---|---|---|---|
| Hgb | Neu | PLT | HFS | |||||
| Tas94 | PLD (20 mg/m2) d1,15 | RES 18 | 28.0 | – | 16.7 | 0 | 0 | 5.5 |
| GEM (2000 mg/m2) d1,15 q28 | ||||||||
| Skarlos95 | PLD (25 mg/m2) d1 | RES 37 | 22 | 2.7 | – | – | – | 2.7 |
| GEM (650 mg/m2) d1,8 q28 | ||||||||
| Holloway96 | PLD (25 mg/m2) d1 | ALL 25 | 64.0 | – | – | 24.0 | 4.0 | – |
| GEM (650 mg/m2) d1,8 | ||||||||
| Karaoglu97 | PLD (25 mg/m2) d1 | RES 35 | 28.6 | 6 | 2.9 | 8.6 | – | 0 |
| GEM (1000 mg/m2) d1,8 q28 | ||||||||
| Petru98 | PLD (30 mg/m2) d1 | RES 31 | 33.0 | 3.8 | 3.0 | 26.0 | 10 | 3.0 |
| GEM (650 mg/m2) d 1,8 q28 | ||||||||
| D’Agostino99 | PLD (30 mg/m2), d1 | RES 36 | 25.0 | – | 7.0 | 32.6 | 8.5 | 10 |
| GEM (1000 mg/m2), d1,8 q21 | SEN 31 | 45.2 | ||||||
| Ferrandina100 | PLD (30 mg/m2), d1 | RES 66 | 21.6 | 5 | 9.0 | 28.8 | 10.8 | 14.4 |
| GEM (1000 mg/m2), d1,8 q21 | SEN 45 | 53.7 | 8.7 | |||||
| Verhaar-Langereis102 | PLD (30 mg/m2), d1 | RES 27 | 28.0 | 7.5 | – | 70.4a | 48.1 | 44.4 |
| TPT (1.0 mg/m2), d1-5 q21 and PLD (40 mg/m2), d1 | ||||||||
| TPT (0.75 mg/m2), d1-5 q21 | ||||||||
| Campos103 | PLD (30 mg/m2), d1, q21 | ALL 37 | 29.0 | – | 2.5 | 40.0 | 0 | 52.5 |
| PTX (70 mg/m2), weekly | RES 24 | 17.0 | ||||||
| for 18 weeks | SEN 13 | 54.0 | ||||||
| Katsaros104 | PLD (30 mg/m2), d1 | ALL 30 | 37.0 | 5.5 | 0 | 4.0 | 0 | 2.0 |
| vinorelbine (30 mg/m2), d1, q21 | ||||||||
| Joly105 | PLD (40 mg/m2), d1 | ALL 98 | 28.0 | – | 7.0 | 48.0 | 3.0 | 2.0 |
| ifosfamide (1700 mg/m2), d1-3 q28 | RES 57 | 19.0 | ||||||
| SEN 41b | 41.0 | |||||||
Abbreviations: GEM, gemcitabine; HFS, hand–foot syndrome; Hgb, anemia; Neu, neutropenia; PFS, progression free survival; RR, response rate; RES, platinum resistant recurrent disease; SEN, platinum sensitive recurrent disease; PLT, platelet toxicity; PTX, paclitaxel; TPT, topotecan; q, every; d, day.
a
leukopenia;
b
platinum-sensitive patients are defined as having a 6–12-month platinum free interval.